Novavax reported $147.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 124.4M 9.9M Jun/2026
Agenus USD 33.7M 500K Mar/2026
AstraZeneca USD 16.21B 830M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Geron USD 60.19M 2.71M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
MannKind USD 101.9M 7.47M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.31M 98.69M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 16.6B 1.57B Sep/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026